Ascentage Pharma presents results from five preclinical studies at AACR meeting

Ascentage Pharma (AAPG) presented results from five preclinical studies during poster presentations at the 2025 American Association for Cancer Research Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois, USA. These poster presentations feature five of the company’s drug candidates: novel tyrosine kinase inhibitor olverembatinib, Bcl-2 inhibitor lisaftoclax, FAK/ALK/ROS1 TKI APG-2449, embryonic ectoderm development inhibitor APG-5918, and IAP antagonist AS03157. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, “The encouraging data from our investigational assets, presented at this year’s AACR Annual Meeting, are another testament to our strong and innovative pipeline. In particular, the combination of olverembatinib and lisaftoclax, two of our key drug candidates, has demonstrated strong synergistic effects in preclinical models of acute myeloid leukemia and T-cell acute lymphoblastic leukemia. These preclinical studies are expected to complement and further catalyze our clinical development. Moving forward, we will actively advance the clinical development of these programs in order to bring more treatment options to patients in need.”